ToolsSeptember 18, 2026via GeekWire
Fewer lab animals, better drugs: This startup wants to fix how experiments get designed
Why it matters
AI is automating the knowledge-synthesis bottleneck in preclinical research. For pharma teams and biotech operators, this shifts resource allocation and experiment velocity — a measurable productivity win in a high-stakes, compliance-heavy workflow.
Key signals
- ModernVivo uses AI to analyze millions of published animal studies
- Customers reduced literature review time from ~1 month to ~1 hour
- Software automates experiment design step traditionally done manually
- Seattle-based startup
- Target: drug researchers and preclinical teams
- ModernVivo uses AI to synthesize millions of published animal studies
- Literature review compressed from ~1 month to ~1 hour for customers
- Target use case: experiment design in preclinical drug research
- Founded in Seattle
- Product addresses both researcher efficiency and reduction in animal testing
The hook
Drug researchers just cut lit review from 30 days to 1 hour. ModernVivo's AI reads millions of animal studies to auto-design experiments.
ModernVivo's software reads millions of published animal studies to help drug researchers design their own experiments, work that has traditionally meant weeks of manual literature review. The Seattle company says customers who once spent a month on that step now spend as little as an hour.